NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Structured Abstract
Context:
Speech and language development is a useful initial indicator of a child's overall development and cognitive ability. Identification of children at risk for delay may lead to interventions, increasing chances for improvement. However, screening for speech and language delay is not widely practiced in primary care.
Objective:
To determine the strengths and limits of evidence about the effectiveness of selecting, testing, and managing children with potential speech and language delay in the course of routine primary care. Key questions examined a chain of evidence about the accuracy and feasibility of screening children age 5 years and younger in primary care settings, role of risk factors in selecting children for screening, effectiveness of interventions for children identified with speech and language delay, and adverse effects of screening and interventions.
Data Sources:
Relevant studies were identified from multiple searches of MEDLINE, PsycINFO, and CINAHL (1966 to November 19, 2004). Additional articles were obtained from recent systematic reviews, reference lists of pertinent studies, reviews, editorials, and websites, and by consulting experts.
Study Selection:
Eligible studies had English-language abstracts, were applicable to U.S. clinical practice, and provided primary data relevant to key questions. Studies of children with previously diagnosed conditions known to cause speech and language delay were not included. Only randomized controlled trials were considered for examining the effectiveness of interventions. Studies with speech and language outcomes as well as non speech and language health and functional outcomes were included.
Data Extraction:
Data were extracted from each study and entered into evidence tables.
Data Synthesis:
Studies were summarized by descriptive methods and rated for quality using criteria developed by the USPSTF. A large descriptive literature of potential risk factors for speech and language delay in children is heterogeneous and results are inconsistent. A list of specific risk factors to guide primary care physicians in selective screening has not been developed or tested. The most consistently reported risk factors include a family history of speech and language delay and learning difficulties, male sex, and perinatal factors.
A total of 44 studies about evaluations taking 30 minutes or less to administer that could be administered in a primary care setting were considered to have potential for screening purposes. Studies included many different instruments, there were no accepted gold standards or referral criteria, and few studies compared the performance of 2 or more tests. Studies utilizing evaluations taking 10 minutes or less and rated good to fair in quality reported wide ranges of sensitivity and specificity when compared to reference standards (sensitivity 17% to 100%; specificity 45% to 100%). Studies did not provide enough information to determine how accuracy varied by age, setting, or administrator.
Fourteen good and fair-quality randomized controlled trials of interventions reported significantly improved speech and language outcomes compared to control groups. Improvement was demonstrated in several domains including articulation, phonology, expressive language, receptive language, lexical acquisition, and syntax among children in all age groups studied and across multiple therapeutic settings. Improvement in other functional outcomes, such as socialization skills, self-esteem, and improved play themes, were demonstrated in some, but not all, of the 4 studies measuring them. In general, studies of interventions were small, heterogeneous, may be subject to plateau effects, and reported short-term outcomes based on various instruments and measures. As a result, long-term outcomes are not known, interventions could not be directly compared, and generalizability is questionable.
Conclusions:
Use of risk factors to guide selective screening is not supported by studies. Several aspects of screening have been inadequately studied to determine optimal methods including what instrument to use, what age to screen, and what interval is most useful. Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited. Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians prior to referral for diagnostic evaluation, non speech and language and long-term benefits of interventions, adverse effects of screening and interventions, and cost.
Keywords:
speech and language delay, preschool children, screening
Contents
- Preface
- Acknowledgements
- 1. Introduction
- 2. Methods
- 3. Results
- Key Question 1. Does Screening for Speech and Language Delay Result in Improved Speech and Language as well as Improved Other Non-speech and Language Outcomes?
- Key Question 2. Do Screening Evaluations in the Primary Care Setting Accurately Identify Children for Diagnostic Evaluation and Interventions?
- 2a. Does Identification of Risk Factors Improve Screening?
- Key Questions 2b and 2c. What Are Screening Techniques and How Do They Differ by Age? What Is the Accuracy of Screening Techniques and How Does It Differ by Age?
- 2d. What Are the Optimal Ages and Frequency for Screening?
- Key Question 3. What Are the Adverse Effects of Screening?
- Key Question 4. What Is the Role of Enhanced Surveillance by Primary Care Clinicians?
- Key Question 5. Do Interventions for Speech and Language Delay Improve Speech and Language Outcomes?
- Key Question 6. Do Interventions for Speech and Language Delay Improve Other Non-Speech and Language Outcomes?
- Key Question 7. Does Improvement in Speech and Language Outcomes Lead to Improved Additional Outcomes?
- Key Question 8. What Are the Adverse Effects of Interventions?
- Key Question 9. What Are Cost-Effectiveness Issues?
- 4. Discussion
- Appendixes
- Appendix 1. Reviewers
- Appendix 2. Search Strategies
- Appendix 3. Inclusion/Exclusion Criteria By Key Question
- Appendix 4. USPSTF Quality Rating Criteria
- Appendix 6. Evidence Table: Studies of Risk Factors
- Appendix 7. Descriptions of Instruments Used in Studies
- Appendix 8. Quality Ratings of Screening Instrument Studies
- Appendix 9. Evidence Table: Randomized Controlled Trials of Interventions
- Appendix 10. Quality Ratings of Intervention Studies
- References
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.1 Contract No. 290-02-0024, Task No. 2. Technical Support of the U.S. Preventive Services Task Force. Prepared by: Oregon Health and Science University Evidence-based Practice Center.2
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers—patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services.
The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
- 1
540 Gaither Road, Rockville, MD 20850. www
.ahrq.gov - 2
3181 SW Sam Jackson Park Road, Portland, Oregon 97239.
- Review Screening for speech and language delay in preschool children: systematic evidence review for the US Preventive Services Task Force.[Pediatrics. 2006]Review Screening for speech and language delay in preschool children: systematic evidence review for the US Preventive Services Task Force.Nelson HD, Nygren P, Walker M, Panoscha R. Pediatrics. 2006 Feb; 117(2):e298-319.
- Review Screening for Lipid Disorders in Children and Adolescents[ 2007]Review Screening for Lipid Disorders in Children and AdolescentsHaney EM, Huffman LH, Bougatsos C, Freeman M, Fu R, Steiner RD, Helfand M, Nelson HD. 2007 Jul
- Review Screening for Speech and Language Delay and Disorders in Children Age 5 Years or Younger: An Evidence Review for the U.S. Preventive Services Task Force[ 2024]Review Screening for Speech and Language Delay and Disorders in Children Age 5 Years or Younger: An Evidence Review for the U.S. Preventive Services Task ForceFeltner C, Wallace IF, Nowell S, Orr CJ, Raffa B, Cook Middleton J, Vaughan J, Baker C, Chou R, Kahwati L. 2024 Jan
- Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force[ 2013]Review Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task ForceLin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E. 2013 Nov
- Review Screening and Interventions for Childhood Overweight[ 2005]Review Screening and Interventions for Childhood OverweightWhitlock EP, Williams SB, Gold R, Smith P, Shipman S. 2005 Jul
- Screening for Speech and Language Delay in Preschool ChildrenScreening for Speech and Language Delay in Preschool Children
- Oncostemum neriifolium voucher CAS:P. Fritsch 1727 atpB-rbcL intergenic spacer, ...Oncostemum neriifolium voucher CAS:P. Fritsch 1727 atpB-rbcL intergenic spacer, partial sequence; chloroplastgi|357540849|gb|JN813468.1|Nucleotide
- Mimulus sessilifolius external transcribed spacer, partial sequenceMimulus sessilifolius external transcribed spacer, partial sequencegi|46392896|gb|AY575339.1|Nucleotide
- Triazolam - Drugs and Lactation Database (LactMed®)Triazolam - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...